TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23432600

Group type: EXPERIMENTAL
Intervention: Triple therapy (20 mg of omeprazole, 500 mg of clarithromycin, and 1000 mg of amoxicillin orally two times daily)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo (omeprazole plus identical placebo)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 21310819

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 22
Study: 19583746

Group type: EXPERIMENTAL
Intervention: Physostigmine (1.8 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17179269

Group type: EXPERIMENTAL
Intervention: TAP block with 20 mL of 0.375% levobupivacaine
Number of subjects: 32
Study: 15140661

Group type: EXPERIMENTAL
Intervention: PDPVT
Number of subjects: 42

Group type: COMPARATOR
Intervention: PD
Number of subjects: 42

Group type: COMPARATOR
Intervention: PD+PP
Number of subjects: 42
Study: 11843383

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium
Number of subjects: 144
Study: 9514542

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 36

Group type: COMPARATOR
Intervention: Polidocanol
Number of subjects: 36
Study: 7913766

Group type: EXPERIMENTAL
Intervention: Block-replace regimen of carbimazole plus thyroxine for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Block-replace regimen of carbimazole plus thyroxine for 12 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HLA markers analysis
Number of subjects: 100
Study: 30172099

Group type: EXPERIMENTAL
Intervention: 60 mg daily oral edoxaban
Number of subjects: 1400

Group type: COMPARATOR
Intervention: VKA-based therapy (international normalized ratio: 2.0-3.0 or 1.6-2.6 in Japan if age ≥ 70 years)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Both edoxaban and VKA-based therapy
Number of subjects: 1400
Study: 25796586

Group type: EXPERIMENTAL
Intervention: Strength training of the hip-flexors (dominant leg) performed three times 10 min per week for 6 weeks, progressing from 15 repetition maximum (RM) to 8 RM.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no strength training).
Number of subjects: 33
Study: 23838975

Group type: EXPERIMENTAL
Intervention: Explosive strength training group (TG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study: 22727160

Group type: EXPERIMENTAL
Intervention: Salmeterol-fluticasone (50/100 μg twice daily)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fluticasone (100 μg twice daily)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Salmeterol (50 μg twice daily)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Salmeterol-fluticasone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fluticasone
Number of subjects: 105
Study: 19719551

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-estradiol + 10 mg dydrogesterone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2 mg 17beta-estradiol + 10 mg dydrogesterone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 18929285

Group type: COMPARATOR
Intervention: levobupivacaine 0.20%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.20% plus sufentanil 0.5 microg kg(‐1)
Number of subjects: 40
Study: 17175700

Group type: EXPERIMENTAL
Intervention: Rifampicin with omeprazole (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 50
Study: 12811706

Group type: EXPERIMENTAL
Intervention: 20 mg of nasal sumatriptan
Number of subjects: 29

Group type: COMPARATOR
Intervention: 30 mg of intravenous ketorolac
Number of subjects: 29
Study: 11179942

Group type: EXPERIMENTAL
Intervention: Oral information only
Number of subjects: 115

Group type: COMPARATOR
Intervention: Combination of oral and written information
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study: 8646433

Group type: EXPERIMENTAL
Intervention: Naloxone (20 mg i.v. infusion)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (RA and controls) after naloxone treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (RA and controls) after any treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Baseline pain score in RA group
Number of subjects: 15
Study: 1815648

Group type: EXPERIMENTAL
Intervention: High NaCl diet (200 mEq/day) in salt-sensitive (SS) men
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High NaCl diet (200 mEq/day) in salt-resistant (SR) men
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low NaCl diet (20 mEq/day)
Number of subjects: 27
Study: 6337421

Group type: EXPERIMENTAL
Intervention: Cephalexin, 250 mg every six hours for 72 hours
Number of subjects: 499

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 499
Study: 30004561

Group type: EXPERIMENTAL
Intervention: TESSYS
Number of subjects: 462

Group type: COMPARATOR
Intervention: Conventional surgical treatment with posterior approach (Control)
Number of subjects: 462
Study: 27318612

Group type: EXPERIMENTAL
Intervention: ALL Curriculum
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 24834977

Group type: EXPERIMENTAL
Intervention: Abatacept treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23131066

Group type: EXPERIMENTAL
Intervention: High-rate therapy (2.5-second delay at heart rate ≥200 bpm)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Delayed therapy (60-second delay at 170-199 bpm, 12-second delay at 200-249 bpm, 2.5-second delay at ≥250 bpm)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Conventional programming (2.5-second delay at 170-199 bpm, 1.0-second delay at ≥200 bpm)
Number of subjects: 1500
Study: 21087922

Group type: EXPERIMENTAL
Intervention: Tailored intervention arms
Number of subjects: 2513

Group type: COMPARATOR
Intervention: Untailored intervention arm
Number of subjects: 2513
Study: 18490498

Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin delta
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subcutaneous epoetin alfa
Number of subjects: 60
Study: 16283958

Group type: EXPERIMENTAL
Intervention: 100 mg of 2% lidocaine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 30 mg of 0.5% bupivacaine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 60 mg of 2% lidocaine and 15 mg of 0.5% bupivacaine
Number of subjects: 85
Study: 12467943

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg meta-chlorophenylpiperazine (MCPP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 mg ipsapirone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10342343

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg per day for 4 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7857144

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 19
Study: 1940815

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 0
Study: 7141761

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) pretreatment (p.o. 5.0 g/24 h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (1.0 or 1.5 g orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pindolol (1 mg i.v.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol (5 mg i.v.)
Number of subjects: 16
Study: 30382499

Group type: EXPERIMENTAL
Intervention: Propofol (PROP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane (SEVO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both Propofol and Sevoflurane
Number of subjects: 60
Study: 30144630

Group type: EXPERIMENTAL
Intervention: COACH intervention (family-centered, community-based, individually-tailored behavioral intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COACH intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (school readiness intervention delivered by the Nashville Public Library)
Number of subjects: 0
Study: 27501160

Group type: EXPERIMENTAL
Intervention: Community-based exercise intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (provided environment and skills only)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Comparison between intervention and control groups
Number of subjects: 136
Study: 25075927

Group type: EXPERIMENTAL
Intervention: Breast milk expression education and support intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 22370834

Group type: EXPERIMENTAL
Intervention: Neural mobilization treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 56
Study: 19581812

Group type: EXPERIMENTAL
Intervention: Transient elastography (FibroScan)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Forns index
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: FibroScan
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MR-spectroscopy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Histologic steatosis
Number of subjects: 45
Study: 18679605

Group type: EXPERIMENTAL
Intervention: Dihuang Zhixue Capsule (DZC), 2 to 3 capsules orally, thrice a day for 3 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA), 3 mg/kg per day for 3 months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups after 2 months treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: After 3 months treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: After 8 weeks treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 41
Study: 16120823

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1590

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1590

Group type: EXPERIMENTAL
Intervention: SBP lowering to 120 mmHg
Number of subjects: 1590

Group type: EXPERIMENTAL
Intervention: SBP below 120 mmHg
Number of subjects: 1590
Study: 14506391

Group type: EXPERIMENTAL
Intervention: Pre-S2/S HBV vaccine (GenHevac-B) 20 micro g, 3 intramuscular injections on days 0, 30, and 60
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 47
Study: 11197317

Group type: EXPERIMENTAL
Intervention: Assisted Self-Help (ASH)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Manual Only (MAN)
Number of subjects: 1069
Study: 9391135

Group type: EXPERIMENTAL
Intervention: cp‐52 (cold-passaged candidate vaccine virus)
Number of subjects: 0
Study: 8459987

Group type: EXPERIMENTAL
Intervention: Ondansetron (32 mg i.v. single dose/day) plus dexamethasone (20 mg i.v. single dose/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Metoclopramide (2 mg/kg or 1 mg/kg i.v. twice a day) plus dexamethasone (20 mg i.v. single dose/day)
Number of subjects: 113
Study: 2428231

Group type: EXPERIMENTAL
Intervention: Intravenous iloprost
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30422750

Group type: EXPERIMENTAL
Intervention: Recovery garments (DPV576-C) worn overnight
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-recovery garments (placebo) worn overnight
Number of subjects: 38
Study: 29261568

Group type: EXPERIMENTAL
Intervention: Fibrinolytic variables measured on day 1 in patients with early thrombocytopenia (group 1) and those who developed it later (group 2).
Number of subjects: 280

Group type: COMPARATOR
Intervention: Fibrinolytic variables measured on day 1 in patients without thrombocytopenia (group 3).
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Thrombin activatable fibrinolysis inhibitor level and in vivo markers of fibrinolysis activation (plasmin‐antiplasmin complex, D‐dimer).
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Coexistence of impaired fibrinolysis and low platelets.
Number of subjects: 280
Study: 27496855

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 3950

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 3950

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3950
Study: 25203878

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (bypass, sleeve or band)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intensive medical weight management (MWM)
Number of subjects: 57
Study: 22782061

Group type: EXPERIMENTAL
Intervention: Nanofill composite
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nanohybrid composite
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Microhybrid composite
Number of subjects: 41
Study: 20579218

Group type: EXPERIMENTAL
Intervention: immunochemical fecal occult blood test (iFOBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: guaiac-based fecal occult blood test (gFOBT)
Number of subjects: 0
Study: 17721254

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local/regional anesthesia techniques
Number of subjects: 0
Study: 16085508

Group type: EXPERIMENTAL
Intervention: On-site presentations of the study's background and aims
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Recruitment strategies for a 12-month randomized tobacco intervention trial
Number of subjects: 185
Study: 12169503

Group type: EXPERIMENTAL
Intervention: Suturing
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 91
Study: 10417499

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg) plus Cimetidine (400 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7648219

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (specific classes not mentioned)
Number of subjects: 18
Study: 2134115

Group type: EXPERIMENTAL
Intervention: Minaprine (200-300 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amitriptyline (50-75 mg daily)
Number of subjects: 60
Study: 7004723

Group type: EXPERIMENTAL
Intervention: Moderate salt restriction (from 200 to 50 mmol/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of moderate salt restriction and high potassium intake (from 80 to 200 mmol/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High potassium intake (from 80 to 200 mmol/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 21
Study: 31509030

Group type: EXPERIMENTAL
Intervention: Direct method (DM)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Standard method (SM)
Number of subjects: 535
Study: 28555454

Group type: EXPERIMENTAL
Intervention: Combined cognitive training with aerobic exercises
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aerobic exercises (control group)
Number of subjects: 32
Study: 25887744

Group type: EXPERIMENTAL
Intervention: 30-minute physically active London 2012 Olympics-themed VFT
Number of subjects: 85

Group type: COMPARATOR
Intervention: 30-minute sedentary version of the same VFT
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Active VFT
Number of subjects: 85
Study: 23438248

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 91
Study: 22231174

Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin (SQH), 5,000 units subcutaneously three times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin (IVH), titrated to an activated partial thromboplastin time of 40-45 s
Number of subjects: 50
Study: 20237042

Group type: EXPERIMENTAL
Intervention: LDC 4% eye drops
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline placebo (PBO)
Number of subjects: 24
Study: 17647293

Group type: EXPERIMENTAL
Intervention: Clevudine 30 mg daily for 24 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17102823

Group type: EXPERIMENTAL
Intervention: Postoperative craniospinal radiation therapy (36Gy+boost 20Gy to the posterior fossa)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Postoperative combination cranio-spinal radiation therapy (same dose as group I) and chemotherapy (vincristine, etoposide, cisplatin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Postoperative craniospinal radiation therapy (group I)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Postoperative combination cranio-spinal radiation therapy and chemotherapy (group II)
Number of subjects: 48
Study: 12195129

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day (titrated to 100 mg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Atenolol 50 mg/day (titrated to 100 mg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 82

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Losartan and Atenolol
Number of subjects: 82
Study: 9457094

Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging
Number of subjects: 60

Group type: COMPARATOR
Intervention: Two-dimensional imaging
Number of subjects: 60
Study: 7880189

Group type: COMPARATOR
Intervention: Disease-modifying interventions (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized, double-blind, placebo-controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responses selected should be quantitative and standardized
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate responses
Number of subjects: 0
Study: 2198294

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5, and 0.75 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pentobarbital (100, 200, and 300 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Triazolam and Pentobarbital
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 7
Study: 7182376

Group type: EXPERIMENTAL
Intervention: Continuous lumbar epidural analgesia for up to 24 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: General anaesthesia (thiopentone-oxygen-nitrous oxide-alcuronium-pethidine sequence with intermittent positive pressure ventilation)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 38
Study: 29987503

Group type: EXPERIMENTAL
Intervention: First Steps (FS) intervention
Number of subjects: 749

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 749
Study: 31311186

Group type: EXPERIMENTAL
Intervention: Basic intervention + 9 contextualized household visits (RANAS approach)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Basic intervention + 9 non-contextualized household visits
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Basic intervention and 1 placebo household visit
Number of subjects: 1500
Study: 28294080

Group type: EXPERIMENTAL
Intervention: Bilateral sequential same-day tympanoplasty
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bilateral staged tympanoplasty performed 3 months apart
Number of subjects: 38
Study: 25641761

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME) and health education, 3 sessions over 1 month, followed by 2 months of home-based PFME.
Number of subjects: 54
Study: 24220392

Group type: EXPERIMENTAL
Intervention: Intra-articular injections of high-molecular-weight hyaluronic acid (HA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs
Number of subjects: 25
Study: 21698811

Group type: EXPERIMENTAL
Intervention: Alverina citrate 60 mg with Simethicone 300 mg three times daily
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Alverina citrate and Simethicone combination
Number of subjects: 409
Study: 19233855

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 15532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15532

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet agents with highest tertile aspirin dose
Number of subjects: 15532
Study: 19164787

Group type: EXPERIMENTAL
Intervention: Danqi Piantang Jiaonang (DJ)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Buchang Naoxintong Jiaonang (Control)
Number of subjects: 605
Study: 15303131

Group type: EXPERIMENTAL
Intervention: Group E (continuous epidural anesthesia)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group G+E (epidural anesthesia combined with general anesthesia)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group G (general anesthesia)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group G+E and Group G
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group E
Number of subjects: 30

Group type: COMPARATOR
Intervention: Groups G+E and G
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group G and Group G+E
Number of subjects: 30
Study: 12296500

Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 453

Group type: COMPARATOR
Intervention: Non-case management
Number of subjects: 453
Study: 9215059

Group type: EXPERIMENTAL
Intervention: diclofenac-gentamicin
Number of subjects: 25

Group type: COMPARATOR
Intervention: betamethasone-neomycin
Number of subjects: 25
Study: 7805704

Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin (PBC)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 225

Group type: COMPARATOR
Intervention: Tenoxicam
Number of subjects: 225
Study: 3303294

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 276

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Sucralfate and Cimetidine
Number of subjects: 276